NeraCare develops and commercializes molecular diagnostic tests for patients with skin cancer.
The tests provide actionable, tumor-specific information for each individual patient. The information is used to make improved treatment decisions, i.e. whether therapy is absolutely necessary or whether a patients' survival estimate is so favourable that it is reasonable to avoid drug therapy and the associated, severe side effects.
Through its partnerships with pharmaceutical companies and leading investigators, NeraCare is at the forefront of designing cutting-edge clinical trials to help expand access to drugs for early stage patients.
Company Details
- Employees
- 10
- Founded
- -
- Address
- Neue Rothofstr. 13-19, Wework,germany
- Industry
- Medical Practices
- NAICS
-
Ambulatory Health Care ServicesOffices of Other Health PractitionersOutpatient Care CentersOther Ambulatory Health Care ServicesOffices of All Other Health PractitionersOutpatient Mental Health and Substance Abuse CentersAll Other Ambulatory Health Care ServicesOffices of PodiatristsBlood and Organ BanksAll Other Miscellaneous Ambulatory Health Care Services
- Website
- melagenix.de
- Keywords
- melanoma, relapse risk, adjuvant therapy, genexpression test, precision medicine, immunotherapy, skin cancer, biomarker, melanoma prognosis, gene expression profile, companion diagnostic, CDx.
- HQ
- Frankfurt
Neracare Questions
Neracare's website is melagenix.de
Neracare's LinkedIn profile is https://de.linkedin.com/company/neracare-gmbh
Neracare has
10 employees.
View email and phone details for 10
employees at Neracare.
Neracare's industry is
Medical Practices
Neracare's top competitors are
Akoya Biosciences, Inc.,
Avelo,
Iron Bridge Gmbh,
Sanofi,
A18i,
Dr. Ackermann Gmbh,
Biocap,
Epigenomics Ag,
Paion Ag,
Biofrontera Group.
Neracare's categories are Medical Practices
Neracare's founding year is 2015
